DataString Consulting Company Logo
DataString Consulting Company Logo
Ranolazine Tablet Market
Home»Top Market Reports»Ranolazine Tablet Market

Ranolazine Tablet Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802147, Published - April 2025

Segmented in Formulation (Immediate Release, Extended Release), Patient Cohort (Elderly, Middle-Aged, Young Adults), Distribution Channel, Prescription Mode and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Ranolazine Tablet Market Outlook

The market, for Ranolazine tablet was estimated at $760.7 million in 2024; and it is anticipated to increase to $1.1 billion by 2030 with projections indicating a growth to around $1.5 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 6.3% over the forecast period. The growth of the ranolazine tablet market can be attributed to several key factors. The increasing prevalence of chronic angina coupled with rising awareness amongst patients and health professionals about effective treatment options, particularly the importance of ranolazine, has propelled this markets relevance. Further, the tablets effectiveness in treating stable angina while also exhibiting a relatively low side-effect profile has encouraged its broader use, making it a cornerstone therapy in this domain. This, coupled with consistent research and development efforts into novel pharmaceutical solutions, continues to drive the market forward.


Ranolazine tablets are a well-established medication primarily used for the treatment of chronic angina - a condition characterized by chest pain caused by reduced blood flow to the heart. Known for their controlled-release mechanism, ranolazine tablets offer sustained relief, lessening the frequency and severity of angina attacks without lowering blood pressure. Furthermore, a growing body of evidence highlighting the potential of ranolazine in managing other cardiac conditions and its compatibility with other medications is fostering deeper interest amongst clinicians and researchers.


Market Size Forecast & Key Insights

2019
$760M2024
2029
$1.4B2034

Absolute Growth Opportunity = $641M

The Ranolazine Tablet market is projected to grow from $760.7 million in 2024 to $1.40 billion in 2034. This represents a CAGR of 6.3%, reflecting rising demand across Angina Pectoris Management, Coronary Artery Disease Treatment and Post-Angioplasty Chronic Conditions.

The Ranolazine Tablet market is set to add $641 million between 2024 and 2034, with manufacturer targeting Middle-Aged & Young Adults Patient Cohort projected to gain a larger market share.

With Technological evolution, and Growing prevalence of angina pectoris, Ranolazine Tablet market to expand 84% between 2024 and 2034.

Opportunities in the Ranolazine Tablet Market

Expanding Rise in Geriatric Population

The geriatric population globally exhibits increased susceptibility towards cardiovascular disorders and chronic angina. At the heart of treating these conditions lies Ranolazine Tablet, catering prevalently to this demographic. The growing geriatric population subsequently represents a significant market for expansion.

Technological Innovations in Drug Delivery Systems and Globalization of Healthcare Infrastructure

Advancements in technology have broadened the scope of innovative drug delivery systems. The incorporation of Ranolazine Tablet into novel delivery systems, such as nanotechnology-based carriers or time-released capsules, can potentially improve patient compliance and therapeutic efficacy. Hence, technological innovations in drug delivery systems present a prolific for Ranolazine Tablet.

Associated with the globalization of healthcare infrastructure, developing countries are witnessing improved access to advanced treatment options. This expansion holds promise for Ranolazine Tablet, given its essential role in managing chronic stable angina, with the market expecting considerable growth in these regions.

Growth Opportunities in North America and Asia-Pacific

Asia Pacific Outlook

The Asia-Pacific region offers an intriguing landscape in the Ranolazine Tablet market due to escalating cardiovascular disease incidences, primarily driven by lifestyle shifts and a rapidly ageing population. The market competition is spurred by the ingress of global pharmaceutical brands seeking to capitalize on the increasing healthcare expenditure. Moreover, governmental interventions focusing on strengthening the healthcare sector and the resultant surge in awareness is a significant driver for Ranolazine Tablet demand. Policy incentives for foreign investment, leading to enhanced distribution networks and supply chain efficiency, present a credible growth opportunity in this region.

North America Outlook

In North America, the requirement for Ranolazine Tablets has surged due to the prevalent cardiovascular complications. With burgeoning healthcare infrastructure and efficient disease management strategies, this region has become a preeminent market for these specific tablets. Moreover, the ongoing propensity towards sedentary lifestyles coupled with the increase in older population demographic prone to heart ailments has further boosted the demand in this region. The competition, correspondingly, is invigorated by innovation and technological advancements. The primary driver for this region is the concerted effort to enhance patient outcomes while reducing hospital stays to bolster the overall efficiency of healthcare systems.

North America Outlook

In North America, the requirement for Ranolazine Tablets has surged due to the prevalent cardiovascular complications. With burgeoning healthcare infrastructure and efficient disease management strategies, this region has become a preeminent market for these specific tablets. Moreover, the ongoing propensity towards sedentary lifestyles coupled with the increase in older population demographic prone to heart ailments has further boosted the demand in this region. The competition, correspondingly, is invigorated by innovation and technological advancements. The primary driver for this region is the concerted effort to enhance patient outcomes while reducing hospital stays to bolster the overall efficiency of healthcare systems.

Asia-Pacific Outlook

The Asia-Pacific region offers an intriguing landscape in the Ranolazine Tablet market due to escalating cardiovascular disease incidences, primarily driven by lifestyle shifts and a rapidly ageing population. The market competition is spurred by the ingress of global pharmaceutical brands seeking to capitalize on the increasing healthcare expenditure. Moreover, governmental interventions focusing on strengthening the healthcare sector and the resultant surge in awareness is a significant driver for Ranolazine Tablet demand. Policy incentives for foreign investment, leading to enhanced distribution networks and supply chain efficiency, present a credible growth opportunity in this region.

Growth Opportunities in North America and Asia-Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, United Kingdom, Japan, Brazil are expected to grow at 4.1% to 6.0% CAGR

2

Emerging Markets : Brazil, India, South Africa are expected to grow at 7.2% to 8.7% CAGR

Market Analysis Chart

The global market dynamics for the Ranolazine Tablet are influenced by a number of factors. The primary driver for Ranolazine Tablet is the increasing demand due to its effectiveness in treating chronic angina. This of tablet has shown significant results in patients who are unable to undergo surgery or other invasive procedures, signaling a remarkable potential for future growth in the health sector.

Recent Developments and Technological Advancement

December 2024

Pharmaceutical giant Pfizer announced a new formulation of the Ranolazine Tablet, enhancing its effectiveness in managing chronic angina.

October 2024

Gilead Sciences secured FDA approval for their novel Ranolazine Tablet designed to provide sustained release, introducing a pivotal turn in its product line-up.

August 2024

Sun Pharmaceuticals launched a new manufacturing facility dedicated to producing topical Ranolazine tablets, promising improved supply chains for global markets.

The healthcare industry has observed a significant rise in the market demand for Ranolazine Tablets. Fueled by the growing incidence of chronic angina conditions worldwide, this medication has taken the forefront in preferred treatment modalities. Its ability to effectively reduce the frequency of angina attacks while improving exercise toleration has led to a steady increase in its uptake.

Impact of Industry Transitions on the Ranolazine Tablet Market

As a core segment of the Pharmaceutical industry, the Ranolazine Tablet market develops in line with broader industry shifts. Over recent years, transitions such as From Branded to Generic and Digital Transformation have redefined priorities across the Pharmaceutical sector, influencing how the Ranolazine Tablet market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

From Branded to Generic:

The pharmaceutical industry has been undergoing a massive shift with the expiration of key patents, leading to a surge in the production of generic drugs. This transition impacts the Ranolazine Tablet market significantly, as generic versions introduce a competitive pricing dynamic. Brands such as Ranexa had exclusivity in the Ranolazine Tablet market, but now with patent expiration, generic Ranolazine tablets are making notable inroads. Ranolazine manufacturers must tactically adapt to these changes to maintain relevance and market share. These developments are not only influencing pricing models but also the way manufacturers market their products.

2

Digital Transformation:

The digital revolution has not only left the pharmaceutical sector untouched. At the forefront of this digital shift is the trend of online pharmacies leading to easier access for the end consumer to medications like Ranolazine Tablet. Besides, it has positively influenced the Ranolazine Tablet market by introducing novel marketing tactics, including personalized advertisements and online consultations.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Ranolazine Tablet market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Technological Evolution, and Continued Market Education

The pharmaceutical industry is also experiencing rapid technological advancements. In particular, Ranolazine Tablet production has also benefitted from these also advances, leading to refinement in production processes, enhanced dissolution, and increased bioavailability. This has also resulted in safer, more effective products. The regulatory authorities requirement for high-quality, consistent products also drives the demand for Ranolazine Tablets, contributing to growth in the sector.
It is also essential to note the role of market education and awareness in driving the Ranolazine Tablet market. The spread of details and benefits of Ranolazine Tablets to healthcare professionals and potential patients has also led to increased knowledge about the drug, leading to more prescriptions and increased utilization.
Ranolazine is also primarily used as a treatment for chronic angina. The rising prevalence of angina globally is also significantly affecting the demand for Ranolazine Tablets. Sedentary lifestyle habits and increased stress levels are also key contributors to the global rise in angina cases, which in turn influences the demand for effective treatments like Ranolazine.

Restraint: Regulatory Challenges

Stringent regulations and compliances pose a challenging task for the expansion of the Ranolazine Tablet market. While these regulations are designed to ascertain the safety and efficiency of healthcare products, they often create a demanding and time-consuming process for market players. The detailed clinical trials and approval process can result in substantial financial investments and extended time to market, thus adversely affecting the market growth.

Challenge: Price Sensitivity

Patients seeking treatment for chronic stable angina, where Ranolazine Tablets are primarily used, tend to be highly price-sensitive due to the long-term use of medication. The high-cost associated with Ranolazine Tablets and lack of generic substitutes are providing barriers to adoption. Even with insurance coverage, the high out-of-pocket costs can deter potential users, thus impeding the growth of the Ranolazine Tablet market.

Supply Chain Landscape

Raw Material Supply

Triveni Interchem Pvt. Ltd.

Enaltec Labs Pvt Ltd

API Production

Vista Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd

Tablet Manufacturing
AstraZeneca / Gilead Sciences Inc
Division & Distribution
Walgreens Boots Alliance / McKesson Corporation
Raw Material Supply

Triveni Interchem Pvt. Ltd.

Enaltec Labs Pvt Ltd

API Production

Vista Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd

Tablet Manufacturing

AstraZeneca

Gilead Sciences Inc

Division & Distribution

Walgreens Boots Alliance

McKesson Corporation

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Chronic Angina Management
Healthcare & Pharmaceuticals
GlaxoSmithKline
Ranolazine tablet is integrated into chronic disease management therapies and is used in conjunction with other drugs for enhanced efficacy
Arrhythmia Treatment
Healthcare & Pharmaceuticals
Pfizer
As a part of unique approach, they leverage Ranolazine tablet in arrhythmia treatment by increasing tolerance to exercise and reducing ventricular arrhythmias
Post-Operative Pain Management
Healthcare & Pharmaceuticals
Sanofi
Ranolazine tablet is incorporated into post-operative pain management to reduce myocardial oxygen consumption, and therefore, associated discomfort.

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Ranolazine Tablet market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Ranolazine Tablet in Post-Angioplasty Chronic Conditions, Coronary Artery Disease Treatment and Angina Pectoris Management

Post-Angioplasty Chronic Conditions

Following angioplasty procedures, Ranolazine Tablets are often prescribed to manage enduring discomfort or symptoms that persist despite intervention. Often in extended-release form, these tablets help to alleviate recurring pain, improving the patients quality of life. Notable market leaders in this field include Pfizer Inc. and Dr. Reddys Laboratories, widely commended for their innovative drug treatment strategies, and reliable after-care regimens.

Coronary Artery Disease Treatment

Ranolazine Tablets also play a crucial role in the treatment of Coronary Artery Disease . The medication acts to increase the supply of blood and oxygen to the heart, thereby reducing the risk of severe cardiac episodes. Major market contenders in this region include Lupin Limited and Sun Pharmaceutical Industries Ltd., both widely celebrated for their exceptional work on Ranolazine Tablet treatment for CAD and their firm market standing.

Angina Pectoris Management

Ranolazine Tablets are chiefly utilized in the management of chronic angina pectoris, a cardiac ailment characterized by chest pain due to insufficient blood supply to the heart. Ranolazine effectively reduces chest discomfort and improves exercise tolerance in patients, making it the treatment of choice for many physicians. Some of the leading players in this industry include well-known pharmaceutical companies like Gilead Sciences and Aurobindo Pharma Limited, which are recognized for their robust product offerings and strong market penetration.

Ranolazine Tablet vs. Substitutes:
Performance and Positioning Analysis

Ranolazine Tablet stands out for its potent angina-relieving properties, compared to alternatives such as nitrates or beta-blockers. Its unique market positioning stems from its patented mechanism of action, underscoring potential growth in the cardiovascular drug industry

Ranolazine Tablet
  • Dronedarone Tablets /
  • Ivabradine Hydrochloride Tablets
    Efficient in treating chronic angina, Extended-release formulation enhancing medication adherence
    Potential side effects like dizziness and nausea, Increased risk of prolonged QT interval on ECG
    Greater accessibility, affordability
    Limited efficacy, potential severe side-effects

Ranolazine Tablet vs. Substitutes:
Performance and Positioning Analysis

Ranolazine Tablet

  • Efficient in treating chronic angina, Extended-release formulation enhancing medication adherence
  • Potential side effects like dizziness and nausea, Increased risk of prolonged QT interval on ECG

Dronedarone Tablets / Ivabradine Hydrochloride Tablets

  • Greater accessibility, affordability
  • Limited efficacy, potential severe side-effects

Ranolazine Tablet stands out for its potent angina-relieving properties, compared to alternatives such as nitrates or beta-blockers. Its unique market positioning stems from its patented mechanism of action, underscoring potential growth in the cardiovascular drug industry

Loading...

Research Methodology

This market research methodology defines the Ranolazine Tablet market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Ranolazine Tablet across {Application Area 1}, {Application Area 2}, and {Application Area 3} Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Gilead Sciences Inc, Teva Pharmaceuticals USA Inc, and Alembic Pharmaceuticals Inc. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Supply, API Production, and Tablet Manufacturing. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Ranolazine Tablet segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Supply (Triveni Interchem Pvt. Ltd., Enaltec Labs Pvt Ltd), API Production (Vista Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd), and Tablet Manufacturing. Our parallel substitute analysis examines Dronedarone Tablets and Ivabradine Hydrochloride Tablets, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Gilead Sciences Inc, Teva Pharmaceuticals USA Inc, and Alembic Pharmaceuticals Inc., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Ranolazine Tablet market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Ranolazine Tablet Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 808 million
Revenue Forecast in 2034USD 1.40 billion
Growth RateCAGR of 6.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024760 million
Growth OpportunityUSD 641 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024760 million USD
Market Size 2027913 million USD
Market Size 20291.03 billion USD
Market Size 20301.10 billion USD
Market Size 20341.40 billion USD
Market Size 20351.49 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredFormulation, Patient Cohort, Distribution Channel, Prescription Mode
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledGilead Sciences Inc, Teva Pharmaceuticals USA Inc, Alembic Pharmaceuticals Inc., Sanofi India Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals USA Inc., Glenmark Pharmaceuticals Ltd., Accord Healthcare Inc., Apotex Corp., Aurobindo Pharma Ltd., Mylan Pharmaceuticals Inc. and Lupin Ltd.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Ranolazine Tablet Market Size, Opportunities & Strategic Insights, by Formulation

4.1Immediate Release
4.2Extended Release
Chapter 5

Ranolazine Tablet Market Size, Opportunities & Strategic Insights, by Patient Cohort

5.1Elderly
5.2Middle-Aged
5.3Young Adults
Chapter 6

Ranolazine Tablet Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Online Pharmacies
6.2Hospital Pharmacies
6.3Retail Pharmacies
Chapter 7

Ranolazine Tablet Market Size, Opportunities & Strategic Insights, by Prescription Mode

7.1Prescription-based
7.2Over-the-counter
Chapter 8

Ranolazine Tablet Market, by Region

8.1North America Ranolazine Tablet Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Ranolazine Tablet Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Ranolazine Tablet Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Ranolazine Tablet Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Ranolazine Tablet Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Ranolazine Tablet Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Gilead Sciences Inc
9.2.2Teva Pharmaceuticals USA Inc
9.2.3Alembic Pharmaceuticals Inc.
9.2.4Sanofi India Ltd.
9.2.5Sun Pharmaceutical Industries Ltd.
9.2.6Zydus Pharmaceuticals USA Inc.
9.2.7Glenmark Pharmaceuticals Ltd.
9.2.8Accord Healthcare Inc.
9.2.9Apotex Corp.
9.2.10Aurobindo Pharma Ltd.
9.2.11Mylan Pharmaceuticals Inc.
9.2.12Lupin Ltd.